Your browser is no longer supported. Please, upgrade your browser.
Settings
STML Stemline Therapeutics, Inc. daily Stock Chart
STML [NASD]
Stemline Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.96 Insider Own9.10% Shs Outstand32.37M Perf Week-7.30%
Market Cap534.11M Forward P/E- EPS next Y-0.91 Insider Trans-5.12% Shs Float26.88M Perf Month-14.95%
Income-71.70M PEG- EPS next Q-0.64 Inst Own68.00% Short Float6.97% Perf Quarter14.98%
Sales0.60M P/S890.18 EPS this Y-36.70% Inst Trans32.89% Short Ratio7.09 Perf Half Y20.88%
Book/sh3.28 P/B5.03 EPS next Y66.70% ROA-82.00% Target Price35.80 Perf Year94.12%
Cash/sh3.07 P/C5.37 EPS next 5Y- ROE-101.90% 52W Range7.30 - 20.55 Perf YTD5.77%
Dividend- P/FCF- EPS past 5Y-10.00% ROI-145.60% 52W High-19.71% Beta0.18
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low126.03% ATR0.70
Employees46 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)26.87 Volatility3.90% 4.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.70% Profit Margin- Rel Volume0.78 Prev Close17.10
ShortableYes LT Debt/Eq0.00 EarningsMay 09 Payout- Avg Volume264.19K Price16.50
Recom1.60 SMA20-11.22% SMA50-9.95% SMA2009.05% Volume204,906 Change-3.51%
Jun-12-18Initiated ROTH Capital Buy $30
Nov-01-17Reiterated H.C. Wainwright Buy $34 → $38
Feb-06-17Reiterated Wedbush Outperform $19 → $11
Mar-15-16Reiterated Wedbush Outperform $19 → $15
Apr-27-15Initiated H.C. Wainwright Buy $38
Apr-22-15Resumed Jefferies Buy
Jan-26-15Reiterated ROTH Capital Buy $62 → $50
Oct-30-13Reiterated Aegis Capital Buy $40 → $70
Jun-19-18 10:00AM  Biotechnology Firm PPCB, Shows Great Potential ACCESSWIRE
Jun-18-18 07:00AM  Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress GlobeNewswire
Jun-15-18 08:15AM  Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress GlobeNewswire
Jun-14-18 07:00AM  Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress GlobeNewswire
Jun-05-18 07:00AM  Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO GlobeNewswire
May-22-18 07:20AM  Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress ACCESSWIRE
May-18-18 07:00AM  Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress GlobeNewswire
May-17-18 07:00AM  Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting GlobeNewswire
May-09-18 04:26PM  Stemline Therapeutics: 1Q Earnings Snapshot Associated Press
04:00PM  Stemline Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 06:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc. Business Wire
May-01-18 01:43PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-30-18 08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-26-18 07:00AM  Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE +7.28%
Apr-05-18 07:00AM  Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 GlobeNewswire
Mar-19-18 07:50AM  Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:30AM  Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-16-18 08:05AM  Stemline Therapeutics reports 4Q loss Associated Press -6.33%
07:30AM  Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-14-18 07:34AM  Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML) Simply Wall St.
Mar-08-18 07:30AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-18 11:02AM  Top 3 Growth Stocks For The Month Simply Wall St.
Jan-26-18 10:21AM  Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock GlobeNewswire +6.41%
Jan-24-18 07:00AM  Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock GlobeNewswire +7.77%
Jan-22-18 04:01PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.17%
Jan-09-18 07:30AM  Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-08-18 02:24PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire -5.12%
Jan-04-18 08:00AM  Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.00%
Dec-26-17 12:11PM  ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 11:02AM  Best-In-Class Growth Stocks Simply Wall St.
09:26AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-13-17 08:47AM  Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment MarketWatch
08:36AM  Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented GlobeNewswire
Dec-08-17 07:00AM  Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Nov-16-17 07:00AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-09-17 05:14PM  Stemline Therapeutics reports 3Q loss Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 12:29PM  Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October Motley Fool -6.01%
Nov-04-17 03:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-02-17 12:35PM  ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017 Capital Cube
Nov-01-17 09:02AM  Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Oct-31-17 04:21PM  The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% Motley Fool +29.38%
12:02PM  Growth Stocks Investors Love Simply Wall St.
07:00AM  Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint GlobeNewswire
Sep-20-17 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-11-17 07:00AM  Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 GlobeNewswire
Sep-08-17 07:30AM  Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 09:14PM  ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-30-17 06:10PM  Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress GlobeNewswire
Aug-24-17 10:51AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 07:30AM  Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-17 05:48PM  Stemline Therapeutics reports 2Q loss Associated Press
07:00AM  Stemline Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-23-17 09:36AM  Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA GlobeNewswire +7.06%
Jun-06-17 07:30AM  Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
May-31-17 08:50AM  Implied Volatility Surging for Stemline Therapeutics (STML) Stock Options Zacks
May-18-17 07:30AM  Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting GlobeNewswire
May-16-17 01:12PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. Business Wire
May-10-17 05:38PM  Stemline Therapeutics reports 1Q loss Associated Press
05:13PM  Stemline Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-02-17 08:30PM  J&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company? PR Newswire
May-01-17 07:00AM  Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-03-17 10:55AM  DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:41AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017 Accesswire
10:32AM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML Accesswire
Mar-31-17 10:50PM  STEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Stemline Therapeutics, Inc. (STML) GlobeNewswire
12:10PM  UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
11:27AM  STML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017 GlobeNewswire
11:09AM  DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:30AM  April 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline Business Wire
Mar-30-17 09:52PM  APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
08:53PM  Deadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc. Business Wire
11:39AM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017 GlobeNewswire
Mar-29-17 06:15PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
05:34PM  DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact The Firm GlobeNewswire
Mar-28-17 02:44PM  SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Stemline Therapeutics, Inc. Business Wire
12:35PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. GlobeNewswire
Mar-27-17 06:26PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
03:22PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Stemline Therapeutics, Inc. - STML PR Newswire
Mar-26-17 08:11AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Stemline Therapeutics, Inc. of Imminent Lead Plaintiff Deadline Accesswire
Mar-24-17 10:50PM  STEMLINE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Stemline Therapeutics, Inc. (STML) Business Wire
05:19PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Stemline Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline STML GlobeNewswire
11:24AM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:33AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017 Accesswire
08:15AM  Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial Accesswire
08:01AM  STEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-23-17 09:48PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors In Stemline Therapeutics, Inc. Of Imminent Lead Plaintiff Deadline PR Newswire -5.03%
01:04PM  STEMLINE THERAPEUTICS INC Financials
07:00AM  Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN GlobeNewswire
Mar-22-17 11:15AM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm Accesswire
09:50AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. Business Wire
Mar-21-17 10:46AM  SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -9.38%
09:24AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 10:27AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017 Accesswire
Mar-18-17 01:18PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc., and Encourages Investors with Losses to Contact the Firm GlobeNewswire
Mar-17-17 04:00PM  Stemline Investors Reminder: Hagens Berman Reminds Investors in Stemline Therapeutics of the April 4, 2017 Lead Plaintiff Deadline GlobeNewswire -6.40%
03:31PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Stemline Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoberman KennethChief Operating OfficerMar 13Sale16.8212,746214,388409,594Mar 14 09:30 PM
Hoberman KennethChief Operating OfficerMar 12Sale17.3817,241299,697422,340Mar 14 09:30 PM
Gionco DavidChief Accounting OfficerMar 12Sale17.389,183159,595180,684Mar 14 09:30 PM
Bergstein IvanChief Executive OfficerMar 12Sale17.3437,857656,4392,156,431Mar 14 09:30 PM
Gionco DavidChief Accounting OfficerMar 07Sale16.561,41323,399152,275Mar 09 09:31 PM
Hoberman KennethChief Operating OfficerMar 07Sale16.553,02750,097369,278Mar 09 09:32 PM
Bergstein IvanChief Executive OfficerMar 07Sale16.566,797112,5582,050,580Mar 09 09:31 PM
Bergstein IvanChief Executive OfficerFeb 27Sale17.2613,407231,4052,057,377Feb 28 09:32 PM
Gionco DavidChief Accounting OfficerFeb 27Sale17.264,58479,120153,554Feb 28 09:32 PM
Hoberman KennethChief Operating OfficerFeb 27Sale17.265,72698,831371,915Feb 28 09:31 PM
Bergstein IvanChief Executive OfficerFeb 26Sale17.6110,776189,7652,070,784Feb 28 09:32 PM
Gionco DavidChief Accounting OfficerFeb 26Sale17.614,40077,484158,138Feb 28 09:32 PM
Hoberman KennethChief Operating OfficerFeb 26Sale17.615,30093,333377,641Feb 28 09:31 PM
Bergstein IvanChief Executive OfficerFeb 15Sale15.803,82060,3562,081,560Feb 16 09:31 PM
Hoberman KennethChief Operating OfficerFeb 15Sale15.671,85129,005382,941Feb 16 09:31 PM
Gionco DavidChief Accounting OfficerJan 17Sale13.434,25057,078162,538Jan 19 09:30 PM
Hoberman KennethChief Operating OfficerJan 08Sale13.9314,040195,577384,792Jan 12 09:31 PM
Hoberman KennethChief Operating OfficerDec 18Sale14.7540590398,832Dec 19 07:58 PM
Hoberman KennethChief Operating OfficerDec 15Sale14.1811,943169,352398,872Dec 19 07:58 PM